DIAGNOS Announces Impressive Results for the Automatic Detection of Age-Related Macular Degeneration Using CARA Algorithms

DIAGNOS Announces Impressive Results for the Automatic Detection of Age-Related 
Macular Degeneration Using CARA Algorithms 
BROSSARD, QUEBEC -- (Marketwired) -- 10/10/13 -- DIAGNOS Inc.
("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in
natural resource and healthcare technical services including,
screening, software and algorithm development, data analysis and
image processing, is pleased to announce new impressive results for
the early automatic detection for people affected by age-related
macular degeneration. 
Age-related macular degeneration (AMD) is a painless irreversible
destruction of the macula (the central area of the eye's retina),
which leads to gradual loss of the sharp, fine-detail, "straight
ahead" vision required for activities like reading, driving,
recognizing faces, and seeing the world in color. Macular
degeneration can be very serious and is the second-highest cause of
irreversible blindness in the world. Macular degeneration is a
leading cause of blindness and visual impairment in older adults
(greater than 50 years). AMD usually affects both eyes, but the speed
at which it progresses can vary from eye to eye. 
"Automatic, fast and robust screening of this widespread disease will
result in early detection and early treatment. Our method achieved an
impressive recognition rate of 93.3%, with a specificity of 95.5% and
a sensitivity of 91.3%. This low cost approach shows results that are
in agreement with medical experts as well as robustness to both image
quality and fundus camera model. We are very proud having achieved
these results and look forward including the new algorithms to the
existing CARA platform as an add-on to be applied on the current
images taken for CARA for early detection of the Diabetic
Retinopathy. This will open a new market and revenue stream to
DIAGNOS", stated Houssem Ben Tahar, Diagnos' Vice- President -
Development and Business Intelligence. 
If detected early, AMD can be treated with either bevacizumab
(Avastin by Genentech/Roche) or ranibizumab (Lucentis by Genentech in
the USA and by Novartis elsewhere) which are injected into the
vitreous humor of the eye at various intervals. Early detection and
treatment can slow the progress of the disease. 
Macular degeneration is a costly and debilitating condition, which
will only become more expensive as the population aged 65 and older
increases. Estimates of the global cost of visual impairment due to
AMD is US$343 billion, including US$255 billion in direct health care
costs. Estimates of the direct health care costs of visual impairment
due to AMD in the US, Canada, and Cuba (World Health Organization sub
region AMR-A), collectively, is approximately US$98 billion. Direct
medical costs of AMD are substantially higher among the population
aged 65 years and older than in the population aged 40 to 64 years. 
Macular degeneration is widespread because of the impending epidemic
of "ageing" in the Western world. Age is a prominent risk factor for
AMD. According to the latest predictions released by the United
Nations, the number of people aged over 60 will triple from 606
million worldwide in 2000 to nearly 2 billion by 2050. The increase
in the population aged over 80 is expected to be more than fivefold,
from 69 million in 2000 to 379 million by 2050. People aged over 60
constitute about 20% of the population in more developed regions of
the world; by 2050 they will probably account for 33% according to
the United Nations. The number of people living with macular
degeneration today is similar to that of those who have all types of
cancer . A large study found that people in middle age have about a
2% risk of getting AMD, but this risk increased to nearly 30% in
those over age 75. Medicare beneficiaries who had AMD in the USA
increased from 5% to 27.1% from 1991 to 1999. 
About CARA 
CARA is a tele-ophthalmology platform that integrates with ophthalmic
imaging equipment (hardware and software) and processes at the point
of care (POC) and comprises: image upload, image enhancement
automated pre -screening, grading by a specialist, and referral to a
specialist. CARA's image enhancement algorithms make standard retinal
images shar per, clearer, and easier to read. CARA is accessible
securely over the internet, and is compatible with all recognized
image formats and brands of fundus cameras, and is EMR compatible.
CARA is a cost-effective tool for screening large numbers of
patients, in real-time and has been approved by regulatory
authorities including Health Canada, US Food and Drug Administration,
and the European Union. CARA is not intended to diagnose, treat,
cure, or prevent diabetic retinopathy or any other disease. 
About DIAGNOS 
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation
with a mission to commercialize technologies combining contextual
imaging and traditional data mining thereby improving decision making
processes. DIAGNOS offers products, services, and solutions to
clients in a variety of fields including healthcare and natural
resources. 
Neither the TSX Venture Exchange nor its Regulation Service Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
For further information on DIAGNOS, please visit our website at
www.diagnos.com or the SEDAR website at www.sedar.com.
Contacts:
Andre Larente
President
DIAGNOS Inc.
(450) 678-8882 ext 224 
Louis Morin
Bid Capital Markets
(514) 845-1101
 
 
Press spacebar to pause and continue. Press esc to stop.